Skip to content

Supportive Health

Getting a sleep study: what to expect and how coverage works

If a GLP-1 has you asking about a sleep study, this is the practical map: why apnea matters more now that one of these drugs treats it, the two kinds of study and what each night is like, the AHI number that grades the result, and how referral and insurance coverage usually work.

By the glp1.how editorial teamReviewed 4 min read

Evidence-backed

Our guide on sleep quality on a GLP-1 keeps arriving at the same instruction: if you snore heavily, wake unrefreshed, or someone has watched you stop breathing at night, get a sleep study. It doesn't say what that involves. This guide covers what a sleep study is, what the night feels like, and how you get one paid for.

Why this comes up so often on a GLP-1

Obstructive sleep apnea and excess weight travel together. Fat around the neck and tongue narrows the airway, so apnea is common in the people starting these medications. It also often goes undiagnosed, because "tired all the time" is easy to blame on everything else.

The stakes changed in December 2024, when the FDA approved tirzepatide (sold as Zepbound) to treat moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication cleared for the condition. That makes a diagnosis more than a label. A documented sleep study can define your OSA severity, guide whether CPAP or an oral appliance fits, and in some cases open a coverage pathway that a vague complaint of fatigue never will. You can't make apnea-specific treatment decisions without first measuring the apnea.

The two kinds of study

Sleep testing comes in two main formats, and which one you get depends on how likely straightforward OSA is.

In-lab polysomnography (PSG) is the comprehensive version, done overnight at a sleep center. A technologist attaches sensors across your scalp, face, chest and legs to record brain waves, eye movement, muscle activity, heart rhythm, airflow, breathing effort and blood oxygen. Because it captures brain activity, it can stage your sleep and catch disorders a simpler test misses. It is considered the gold standard. Sleeping wired up in a strange room feels odd, and many people don't sleep as well as at home, but the AASM notes that nearly everyone falls asleep and that this typically doesn't affect the results. In-lab testing also costs more and often requires prior authorization.

A home sleep apnea test (HSAT) is a small kit you take home and wear overnight in your own bed. It measures breathing and blood oxygen, and some devices also record heart rate; it doesn't record brain waves. That means it can confirm moderate-to-severe OSA but isn't designed to stage sleep or diagnose more complex conditions. It is cheaper and more convenient, and many insurers prefer it as the first test for uncomplicated suspected apnea. If a home test comes back inconclusive, or it's negative but your symptoms don't fit, the next step is usually an in-lab study anyway.

A rough rule: clear, classic apnea symptoms in an otherwise healthy adult tend toward a home test first. Anything complicated (heart or lung disease, a suspected sleep disorder other than apnea, or an equivocal home result) points to the lab.

The number that grades it: AHI

Both tests produce the same headline metric, the apnea-hypopnea index (AHI): the average number of times per hour your breathing stops (apnea) or becomes shallow enough to drop your oxygen or wake you (hypopnea). The American Academy of Sleep Medicine's severity bands for adults are:

  • Normal: fewer than 5 events per hour
  • Mild OSA: 5 to under 15 events per hour
  • Moderate OSA: 15 to under 30 events per hour
  • Severe OSA: 30 or more events per hour

The moderate threshold matters for GLP-1 users in particular. Zepbound's OSA approval is for the moderate-to-severe range, an AHI of 15 or higher, so the number your study produces can be the difference between "monitor it" and "here's a treatment we can act on." AHI is never read in isolation, though; a good clinician weighs it against your oxygen dips, your symptoms and your other conditions.

How referral and coverage usually work

Sleep testing runs through the medical benefit. The specifics vary by plan, so treat what follows as the usual pattern as of September 2026, not a promise.

The request needs to come from a clinician. Medicare's national coverage rule for OSA sleep testing, for example, covers in-lab and home tests for people with signs and symptoms of OSA, and denies tests not ordered by a treating physician or qualified practitioner. Often that's your primary care provider, who screens your symptoms and either orders a home test directly or refers you to a sleep specialist. Many private plans also require that referral before they'll cover a specialist visit or the study itself.

Coverage usually depends on documented medical necessity: recorded symptoms like loud snoring, witnessed breathing pauses or unrefreshing sleep, plus a clinician's order. A study ordered on a clear symptom record is the version insurers pay for; a self-referred test often isn't covered.

Because home tests cost less, some plans require you to try one first and will only authorize in-lab polysomnography if the home result is inconclusive or your case is complex. In-lab studies more often carry a prior-authorization requirement.

The mechanics are the same ones covered in our insurance coverage guide: benefit design, prior authorization and medical-necessity documentation, pointed at a test instead of a drug. The most useful move is the same too. Call your plan before you book and ask which test they cover first, whether prior authorization applies, and what your share of the cost will be against your deductible. If the symptoms fit, raise it with your prescriber, get the symptoms documented, and let the AHI turn a vague suspicion into a number you can act on.

This is general education, not medical advice. Which sleep test is right for you, what your specific plan covers, and how to act on the result are conversations for your care team and your insurer.

sleep-studypolysomnographyhome-sleep-apnea-testobstructive-sleep-apneaosaahiinsurancecoveragesupportive-health

Common questions

Questions people often ask about this topic.

  • Why does a sleep study come up so often once I'm on a GLP-1?

    Obstructive sleep apnea and excess weight travel together (fat around the neck and tongue narrows the airway), so apnea is common in the people starting these medications, and it often goes undiagnosed. What raised the stakes is that since December 2024, tirzepatide (sold as Zepbound) has been FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. A documented study can define your OSA severity and guide treatment decisions that a vague complaint of fatigue never will.

  • What's the difference between an in-lab sleep study and a home test?

    In-lab polysomnography (PSG) is the comprehensive overnight version at a sleep center, with sensors recording brain waves, breathing, heart rhythm and oxygen. It can stage your sleep and is considered the gold standard, but costs more and often needs prior authorization. A home sleep apnea test (HSAT) is a small kit you wear overnight in your own bed. It measures breathing rather than brain waves, so it can confirm moderate-to-severe OSA but isn't designed for complex cases. Clear, classic symptoms tend toward a home test first; complicated cases point to the lab.

  • What is the AHI number and what counts as sleep apnea?

    Both tests produce the apnea-hypopnea index (AHI), the average number of times per hour your breathing stops or becomes shallow enough to drop your oxygen or wake you. The American Academy of Sleep Medicine's adult bands are: fewer than 5 events per hour is normal, 5 to under 15 is mild, 15 to under 30 is moderate, and 30 or more is severe. Zepbound's OSA approval is for the moderate-to-severe range (an AHI of 15 or higher), though a good clinician always weighs the number against your oxygen dips, symptoms and other conditions.

  • Will my insurance cover a sleep study?

    Sleep testing runs through the medical benefit, and coverage usually depends on documented medical necessity: recorded symptoms like loud snoring, witnessed breathing pauses or unrefreshing sleep, plus a clinician's order. Medicare, for example, denies sleep tests not ordered by a treating physician or qualified practitioner. Many plans expect the request to come from your primary care provider, and some require you to try a cheaper home test before authorizing an in-lab study. Specifics vary by plan, so call your plan before you book and ask which test they cover first, whether prior authorization applies, and what your share of the cost will be.

  • How do I actually get a sleep study started?

    If the symptoms fit, raise it with your prescriber or primary care provider, get the symptoms documented, and confirm coverage before you book. A study ordered on a clear symptom record is the version insurers pay for, while a self-referred test often isn't covered. From there the AHI can turn a vague suspicion into a number you and your care team can act on.

Evidence

The sources behind this article, labeled by type and strength.

Supporting5

  • Sleep Study — what to expect from polysomnography and home sleep apnea testing (external link)

    American Academy of Sleep Medicine (Sleep Education) · Clinical guideline · Strong evidence

    (2020)

    AASM patient resource (September 2020, physician-reviewed) describing in-lab polysomnography: what it records, that many patients don't sleep as well as at home but this 'typically does not affect the results' and 'nearly everyone falls asleep'. Basis for the in-lab section.

  • Obstructive Sleep Apnea (external link)

    American Academy of Sleep Medicine (Sleep Education) · Clinical guideline · Strong evidence

    (2020)

    AASM overview of OSA (August 2020; page modified 2025): repeated airway blockage during sleep, its link to excess weight, symptoms (snoring, witnessed pauses, unrefreshing sleep), diagnosis by in-lab study or home test, and that home testing suits people with many risk factors and no other conditions. Supports the 'why this comes up' and two-types sections. (AHI severity bands are sourced to the AASM clinical guideline row.)

  • Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (external link)

    New England Journal of Medicine · Peer-reviewed study · Strong evidence

    Malhotra A, Grunstein RR, Fietze I, et al. (2024) · New England Journal of Medicine

    doi:10.1056/NEJMoa2404881

    SURMOUNT-OSA phase 3 trials: tirzepatide roughly halved the apnea-hypopnea index in adults with moderate-to-severe OSA and obesity. Basis for the FDA's December 2024 approval of Zepbound as the first drug for moderate-to-severe OSA, the reason a documented AHI now carries treatment weight.

  • Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults (external link)

    Journal of Clinical Sleep Medicine · Clinical guideline · Strong evidence

    Epstein LJ, Kristo D, Strollo PJ, et al. (2009) · J Clin Sleep Med

    AASM Adult OSA Task Force clinical guideline (PMID 19960649): OSA severity must be measured by objective testing before treatment; defines severity bands used here (mild 5 to <15, moderate 15 to 30, severe >30 events/hour).

  • National Coverage Determination 240.4.1: Sleep Testing for Obstructive Sleep Apnea (OSA) (external link)

    Centers for Medicare & Medicaid Services · Clinical guideline · Strong evidence

    (2009)

    Medicare NCD 240.4.1 (effective March 3, 2009; checked September 2026): covers Type I in-lab PSG and Type II-IV/home devices for beneficiaries with signs and symptoms of OSA; tests not ordered by a treating physician or qualified treating practitioner are denied as not reasonable and necessary. Basis for the referral paragraph.

Revision history

Updated 5 times since Jul 18, 2026 · show changes
  1. v6

    Evidence sources 3 → 5

  2. v5

    Common questions revised

  3. v4

    Summary rewritten; Body revised

  4. v3

    Body revised

  5. v2

    Body revised

  6. v1

    Change tracking began

Related guides

  • CPAP as the weight comes off: managing sleep apnea on a GLP-1 · Tirzepatide (Zepbound) roughly halved sleep apnea severity in the SURMOUNT-OSA trials, and 42 to 50% of participants reached the trial's definition of resolution. That still left many with apnea, and the trials never tested stopping CPAP for good. This guide covers why you shouldn't retire your machine on your own, how pressure and mask fit change as weight comes off, when and how a repeat sleep test happens, and how an OSA diagnosis affects Zepbound coverage (as of September 2026).
  • Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection · Sleep is the quiet variable in GLP-1 treatment. Short sleep can shift weight loss away from fat and toward muscle, GI side effects and hunger changes can disturb the night, and one GLP-1 medication is now FDA-approved to treat obstructive sleep apnea itself. This guide covers how sleep stages work, how treatment can affect them, and why protecting deep sleep helps protect your muscle.
  • Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps · Losing a lot of weight usually costs a small amount of bone, mostly at the hip, and GLP-1 weight loss is no exception. So far the fracture data are reassuring and the drug itself does not look like the main cause, but the long-term evidence is thin. Here's what the bone-density and fracture studies show, who should pay the most attention, and the levers that kept bone steady in trials: resistance and impact training, protein, calcium and vitamin D, and a well-timed bone scan.
  • How GLP-1 medications affect men vs. women: what the sex differences actually are · The same GLP-1 medication doesn't act quite the same in men and women. On average women lose more weight, report more side effects, and absorb more of the drug at the same body weight, differences driven partly by estrogen and testosterone. This guide covers what the research shows about sex differences in weight loss, tolerability, blood sugar and biology, and what it means for what you should expect.
  • Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching · For women, the biggest GLP-1 question is fertility. Tirzepatide can make the pill less reliable, weight loss can bring back ovulation you weren't expecting, and none of these drugs is safe in pregnancy, which is why "Ozempic babies" happen. This guide covers contraception and pregnancy planning, the PCOS trial evidence, protecting bone and muscle, the heart, and the menopause overlap.
  • Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching · For men, losing weight on a GLP-1 can raise testosterone that obesity was holding down, and unlike testosterone therapy it seems to leave fertility intact. This guide covers what the research shows so far on testosterone, sexual function and sperm, muscle and bone, heart health and sleep apnea, and why the routine checkup matters more on these medications.

Related terms

  • Obstructive sleep apnea · A sleep disorder in which the airway repeatedly collapses during sleep, causing brief pauses in breathing; it is closely linked to obesity.
  • Tirzepatide · A once-weekly dual GIP and GLP-1 receptor agonist made by Eli Lilly, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.
  • Zepbound · Eli Lilly's brand name for injectable tirzepatide, FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
  • Polysomnography · An overnight, in-lab sleep study that records brain activity, breathing, blood oxygen, heart rhythm, and movement to diagnose sleep disorders — the gold-standard test for obstructive sleep apnea.
  • Prior authorization · Approval your insurer requires before it will cover a medication.
  • Apnea-hypopnea index (AHI) · The number of complete (apnea) and partial (hypopnea) breathing interruptions per hour of sleep, measured in a sleep study; it grades obstructive sleep apnea as mild (5–14), moderate (15–29), or severe (30+).
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.
  • Medical necessity · The insurer's determination that a treatment is required to diagnose or treat a condition, often required for coverage approval.

Was this helpful?

Improve this page